Caplyta (lumateperone) was approved for the treatment of schizophrenia in 2019 and for depressive episodes linked to bipolar I or bipolar II disorder (bipolar depression) in 2021. Caplyta can be ...

Shares in Intra-Cellular Therapies rose sharply after it reported that its only product Caplyta was effective for a new indication, major depressive disorder (MDD), in a phase 3 trial. Caplyta ...

You've probably seen the commercial for the drug Caplyta which is supposed to help with depressive symptoms of bipolar I and bipolar II. Featuring mostly young adults, the advert starts off by ...

(Sandoz) resolving patent litigation related to Intra-Cellular Therapies’ product CAPLYTA® (lumateperone). The litigation, which is pending in the U.S. District Court for the District of New Jersey, ...

The deal values Intra-Cellular at $14.6 billion. The centerpiece of the Intra-Cellular acquisition is Caplyta, a drug that won its initial FDA approval in 2019 as a treatment for schizophrenia in ...

The company currently has only one marketed drug in its portfolio, Caplyta (lumateperone 42 mg). The FDA initially approved Caplyta for the treatment of schizophrenia in adults in December 2019 ...

(Sandoz) resolving patent litigation related to Intra-Cellular Therapies' product CAPLYTA® (lumateperone). The litigation, which is pending in the U.S. District Court for the District of New Jersey, ...

The deal would allow J&J to gain access to Intra-Cellular's oral therapy, Caplyta, which is approved in the U.S. to treat schizophrenia and depressive episodes associated with bipolar disorder ...

Caplyta, Intra-Cellular Therapies' approved drug for schizophrenia and bipolar depression, shows promise for expanded depression indications Brand New Membership Level: Benzinga Trade Alerts Intra ...